dc.creator | Zhang, Qiang | es |
dc.creator | Pizzorno, Andrés | es |
dc.creator | Miorin, Lisa | es |
dc.creator | Bastard, Paul | es |
dc.creator | Gervais, Adrián | es |
dc.creator | Le Voyer, Tom | es |
dc.creator | Retamar Gentil, Pilar | es |
dc.creator | Sánchez Céspedes, Javier | es |
dc.creator | Cordero Matia, María Elisa | es |
dc.creator | Casanova, Jean-Laurent | es |
dc.date.accessioned | 2023-10-06T13:34:20Z | |
dc.date.available | 2023-10-06T13:34:20Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Zhang, Q., Pizzorno, A., Miorin, L., Bastard, P., Gervais, A., Le Voyer, T.,...,Casanova, J. (2022). Autoantibodies against type I IFNs in patients with critical influenza pneumonia. JOURNAL OF EXPERIMENTAL MEDICINE, 219 (11), e20220514. https://doi.org/10.1084/jem.20220514. | |
dc.identifier.issn | 0022-1007 | es |
dc.identifier.issn | 1540-9538 | es |
dc.identifier.uri | https://hdl.handle.net/11441/149540 | |
dc.description.abstract | Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine
disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-α2 alone (five patients) or with IFN-ω (eight
patients) from a cohort of 279 patients (4.7%) aged 6–73 yr with critical influenza pneumonia. Nine and four patients had
antibodies neutralizing high and low concentrations, respectively, of IFN-α2, and six and two patients had antibodies
neutralizing high and low concentrations, respectively, of IFN-ω. The patients’ autoantibodies increased influenza A virus
replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly
higher than that in the general population for patients <70 yr of age (5.7 vs. 1.1%, P = 2.2 × 10−5
), but not >70 yr of age (3.1 vs.
4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both
IFN-α2 and IFN-ω (OR = 11.7, P = 1.3 × 10−5
), especially those <70 yr old (OR = 139.9, P = 3.1 × 10−10). We also identified 10
patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for ∼5% of cases of life threatening influenza pneumonia in patients <70 yr old. | es |
dc.format | application/pdf | es |
dc.format.extent | 29 p. | es |
dc.language.iso | eng | es |
dc.publisher | ROCKEFELLER UNIV PRESS | es |
dc.relation.ispartof | JOURNAL OF EXPERIMENTAL MEDICINE, 219 (11), e20220514. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Autoantibodies | es |
dc.subject | Type I IFNs | es |
dc.subject | Pneumonia | es |
dc.subject | Critical influenza pneumonia | es |
dc.title | Autoantibodies against type I IFNs in patients with critical influenza pneumonia | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://rupress.org/jem/article/219/11/e20220514/213469/Autoantibodies-against-type-I-IFNs-in-patients | es |
dc.identifier.doi | 10.1084/jem.20220514 | es |
dc.journaltitle | JOURNAL OF EXPERIMENTAL MEDICINE | es |
dc.publication.volumen | 219 | es |
dc.publication.issue | 11 | es |
dc.publication.initialPage | e20220514 | es |